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Abstract 
99mTc-cAbVCAM1-5 is a single-domain antibody fragment (sd-Ab) directed against 
mouse/human Vascular Cell Adhesion Molecule 1 (VCAM-1) which has recently been 
proposed as a new imaging agent for the detection of inflamed atherosclerotic lesions. 
Indeed, in a mouse model of atherosclerosis, 99mTc-cAbVCAM1-5specifically bound to 
VCAM-1 positive lesions, thereby allowing their identification on SPECT images. The 
purpose of the present study was to investigate 99mTc-cAbVCAM1-5 imaging sensitivity using 
a reference statin therapy. 
Methods.ThirtyApoE-deficient mice were fed a western-type diet. First, the relationship 
between the level of VCAM-1 expression and 99mTc-cAbVCAM1-5 uptake was evaluated in 
18 mice using immunohistochemistry and autoradiography (ARG). Second, longitudinal 
SPECT/CT imaging was performed on control (n=9) or atorvastatin-treated mice (0.01% w/w, 
n=9). 
Results.99mTc-cAbVCAM1-5 uptake in atherosclerotic lesionscorrelated with the level of 
VCAM-1 expression (P<0.05).Atorvastatin exerted significant anti-atherogeniceffects, and 
99mTc-cAbVCAM1-5 lesion uptake was significantly reduced in 35 weeks-old atorvastatin-
treated mice, as indicated by ex vivo gamma-well counting and ARG (p<0.05). Contrast-CT 
based SPECT imaging quantification was reproducible (inter experimenter ICC = 0.97, intra 
experimenter ICC = 0.90), and yielded results that were highly correlated with tracer 
biodistribution (r=0.83; P<0.0001). Therefore, reduced 99mTc-cAbVCAM1-5 uptake in 
atorvastatin-treated mice was successfully monitored non-invasively by SPECT/CT imaging 
(0.87 ± 0.06 %ID/cm3 vs 1.11 ± 0.09 %ID/cm3 in control group, P<0.05). 
Conclusions. 99mTc-cAbVCAM1-5 imaging allowed the specific, sensitive and reproducible 
quantification of VCAM-1 expression in mice atherosclerotic lesions. 99mTc-cAbVCAM1-5 
therefore exhibits suitable characteristics for the evaluation of novel anti-atherogenic agents.. 
 
Keywords: 99mTc-cAbVCAM1-5, Atherosclerosis, VCAM-1, Molecular Imaging  
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Introduction. 
 
Atherosclerosis constitutes a worldwide health challenge(1). Despite major advances in 
imaging technologies(2), a major need for imaging probes targeting vulnerable plaques (VP) 
still exists. Such a tool could be used for diagnosis and prognosis as well as for the 
monitoring of treatment efficacy(3). A major criterion for the identification of VP is 
inflammation(4). Vascular cell adhesion molecule 1 (VCAM-1) plays a major role in the 
infiltration of inflammatory cells into atherosclerotic lesions (5). Indeed, in human 
atherosclerotic lesions, VCAM1 expression was observed at the level of the luminal 
endothelium as well as on neovessels, macrophages and activated smooth muscle cells of 
advanced lesions(5–7). Therefore, the assessment of VCAM-1 expression levels in 
atherosclerotic plaques could potentially be highly relevant in order to identify prone-to-
rupture lesions (8). Due to the small size and location of VP, imaging agents with optimal 
characteristics are required. Single domain antibody (sdAb)-derived radiotracers, that have 
originally been developed in the field of oncology(9), have recently been proposed by our 
group as a new class of imaging agents with optimal characteristics for cardiovascular 
imaging(10)and the radiolabelled anti-VCAM-1 camel antibody fragment99mTc-cAbVCAM1-5 
compound was selected among 10 VCAM-1-specific sdAbas the most potent candidate. 
Accordingly, aortic plaques were successfully visualized non-invasively by single photon 
emission computed tomography (SPECT) in an Apolipoprotein E (ApoE) deficient mouse 
model of atherosclerosis, with binding specificity being further demonstrated by in vivo 
competition experiments. Importantly, the production and selection processes of VCAM-1 
sdAbwere specifically designed to produce cross-reactive,murine & human binders. The 
nanomolar affinity of99mTc-cAbVCAM1-5 for both human and murine VCAM-1 therefore 
makes the tracerpotentially suitable for clinical translation(10). 
 
The main objective of the present study was to investigate the sensitivity of 99mTc-
cAbVCAM1-5 for the imaging of VCAM-1 expression in murine atherosclerotic lesions. 
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Indeed, high sensitivity is a key requirement for VP imaging as well as for the preclinical 
assessment of the efficacy of novel anti-atherogenic therapies. In accordance with the major 
role of inflammatory processes in the development of VP, the anti-inflammatory effect of new 
therapeutic agents targeting at the lipid profile such as cholesteriylesterasetransfert protein 
inhibitors is currently being investigated(11). In addition, therapeutic interventions aimed at 
directly targeting the inflammatory process are also under evaluation(3) using drugs such as 
methotrexate, canakinumab or losmapimod(12–14). A specific and sensitive imaging agent 
targeting at the inflammatory process occurring in atherosclerotic lesions would therefore be 
of great relevance for the evaluation of novel anti-atherogenic agents. 
 
Statins are well established and widely used therapeutics in clinical practice, and atorvastatin  
has previously been employed for the evaluation of new imaging agents in mouse models of 
atherosclerosis(15–17).In the present preclinical study, atorvastatin was used in order to 
evaluate the potential of 99mTc-cAbVCAM1-5for the monitoring of treatment efficacy in ApoE 
deficient mice. 
 
Methods 
 
Animal model 
All experimental procedures werein accordance with institutional guidelines and approved by 
the Animal Care & Use committee (ComEth) of the University ofGrenoble. 
Twelve (12) 40-wks old female ApoE-deficient mice (Charles River) fed a western type diet 
were used for the ex vivo comparison between 99mTc-cAbVCAM1-5 uptake in atherosclerotic 
lesions and VCAM-1 expression. 
Eighteen female ApoE-deficient mice were used for the non invasive evaluation of a 
reference therapy.At the age of 15 weeks, mice were either fed a western diet (control group, 
n=9) or a western diet supplemented with a reference therapy (0.01% atorvastatin) (treated 
group, n=9). In these two groups, average food consumption and animal weight were 
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assessed weekly and blood sampling was performed before and 10 weeks following the 
onset of western diet for total cholesterol determination (BioMerieux). The effect of the statin 
therapy on 99mTc-cAbVCAM1-5 uptake in atherosclerotic lesions was evaluated in vivo using 
longitudinal SPECT/CT imaging on 25 and 35 weeks-old mice, and ex vivo by gamma well 
counting (GWC) and autoradiography. 
 
Radiolabeling. 
 
cAbVCAM1-5 labeling with 99mTc was performed as previously described(10). Briefly, 
[99mTc(H20)3(CO)3]
+ (99mTc-tricarbonyl) was synthesized by adding 1 mL of 99mTcO4
- solution 
to an Isolink kit (PSI). The vial was incubated at 100°C for 20 min and neutralized with HCl. 
Then, 0.5mL of 99mTc-tricarbonyl was added to 50 µg of cAbVCAM1-5 and 50 μl of 50mM 
carbonate buffer pH 8.0, and this mixture was incubated for 90 min at 50°C. The 99mTc- 
cAbVCAM1-5 solution was further gelfiltrated on Sephadex G25 (NAP-5; GE Healthcare) and 
filtered (0.22 µm Millex, Millipore). Radiochemical purity, determined by RP-HPLC, was 
>95% up to 6h following radiolabelling. 
 
99mTc-cAbVCAM1-5 uptake versus VCAM-1 expression.99mTc-cAbVCAM1-5 uptake in 
atherosclerotic lesions and VCAM-1 expression level were determined using 
autoradiographicimagingand immunohistochemistry , respectively (n=12). Three (3) hours 
following intraveinousinjection of 37±3MBq (mean±SD), mice were euthanized using CO2. 
The aortic arch was cleaned in 10% formalin (Sigma) under a binocular (Discovery V8, 
Zeiss), embedded in optimal cutting temperature (OCT) medium and frozen in -
40°Cisopentane. Serial 20μm or 8μm-thick adjacent slices were obtained for 
Autoradiography and immunohistochemistry, respectively (HM 505E, Microm).For the 
purpose of this study, longitudinal orientation was preferred for it allowed simultaneous 
examination of several lesions, located in the ascending aorta, small curvature of the aortic 
arch, innominate, left common carotid and left subclavian arteries, and descending aorta. 
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Autoradiography 
Autoradiographieswere acquiredusing overnight exposure with a phosphor-Imager (BAS-
5000, Fujifilm). All slices were then stained using standard hematoxylin-eosin-
safrantrichrome staining (HES), digitalized, andHES and autoradiographicimages were 
coregistered using GIMP2 and ImageJsoftwares. Regions of interest (ROIs) were drawn on 
atherosclerotic lesions based on HES staining. Internal references with known amounts of 
radioactivity were used to express tracer activity as percent injected dose per gram 
(%ID/g)following background and decay correction. 
 
Immunohistochemistry 
VCAM-1 immunostaining(sc-1504, santa-Cruz) was performedas previously 
described(10)onslices adjacent to those used for autoradiography / HES. VCAM-1 
expression level in atherosclerotic lesions (n=94) was ranked as low, moderate or strong by 
a trained observer blinded to the autoradiographicimages. This analysis was reproduced 2 
months later by the same observer in order to assess the reproducibility of themethodology. 
 
Non invasive evaluation of a reference therapy. 
 
SPECT/CT imaging 
SPECT/CT acquisitions were performed two hours following an intravenous injection of 55±5 
MBq(mean±SD) of 99mTc-cAbVCAM1-5.The mice were anesthetized using isoflurane 1.5% in 
a 1:1 mixture of room air and oxygen, and then placed in a temperature-controlled bed for 
SPECT/CT acquisitions focused on the thoracic region (nanoSPECT, Bioscan). First, the 
helicoidal SPECT acquisition was performed with 4 heads equipped with multi-pinholes 
collimators (9 x 1.4 mm diameter pinhole per head) using 24 projections and 45 min of 
acquisition. Then, a fast, 1.5min-long CT acquisition was performed immediately following 
retro-orbital injection of 150µl of a vascular contrast agent (Hexabrix), using the following 
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acquisition parameters: 65kvp, 180 projections and 500ms per projection. Contrast-CT and 
SPECT acquisitions were reconstructed fused and quantified using dedicated software 
(InVivoScope). 
 
SPECT/CT quantification 
Contrast-CT based SPECT quantification was performed blinded to the SPECT images. 
Briefly, 4 Volumes of Interest (VOIs) of 2.2mm3each were drawn at the level of the aortic 
sinus and ascending aorta based on contrast-CT images. 99mTc-cAbVCAM1-5 activity was 
expressed as apercent injected dose per cube centimeter (%ID/cm3) and uptake in 
atherosclerotic lesions was defined as the maximumvalue fromquantification of 4 VOIs. 
Moreover, in order to assess the inter and intra-observer variability, 35 weeks SPECT 
images were further quantified by 3 additional independent experimenters, and this 
quantification was reproduced 2 weeks later by one of the experimenters. 
 
Ex vivo quantification 
Following SPECT/CT imaging, anesthetized mice were euthanized using CO2 and ascending 
aortas including the aortic sinus were carefully harvested along with major organs. Tissue 
samples were weighed and their activity was determined by GWC (Wizard2, Perkin). The 
results were corrected for background and decay and expressed as a percent of injected 
dose per gram of tissue (%ID/g). Adjacent transversal 40- and 10μm-thick cryosections were 
obtained at the level of the aortic sinus for autoradiographicimaging and immunostaining, 
respectively, and autoradiography quantification was performed following HES staining as 
described above. ROIs were also used to determine lesion area in mm2. 99mTc-cAbVCAM1-5 
uptake was expressed as a %ID per gram of lesion (“concentration”) based on internal 
references.Alternatively, lesion volumein the analyzed slice was determined as the product 
between its surface and the slice thickness (40µm), and 99mTc-cAbVCAM1-5 uptake was then 
expressed as a %ID present in the analyzed slice (“total uptake”). 
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Statistical analysis. 
All results are presented as mean±s.e.m. F-test was employed for variances comparisons. 
Student t, Mann &Witney U, Pearson,intraclass coefficient (ICC) and Kappa tests were 
employed forpaired/unpaired datasets with equal variances, unpaired datasets with unequal 
variances,correlation analysis,and inter/intra experimenters variability, respectively. 
Differences were considered significant for P<0.05. 
 
Results 
 
99mTc-cAbVCAM1-5 uptake versus VCAM-1 expression. 
Heterogeneous VCAM-1 expression levels were observed following immunostainingof 
longitudinal slices from the aortic arch of Apo-deficient mice (figure 1A&C). VCAM-1 was 
expressed by endothelial as well as intra-plaque cells. Intra-observer ranking of VCAM-1 
expression level was found to be reproducible (kappa=0.70). Robust 99mTc-cAbVCAM1-5 
uptake was observed following autoradiographicimaging of VCAM-1 positive lesions (figure 
1B&D). Autoradiographyquantification confirmed the relationship between 99mTc-cAbVCAM1-
5 uptake and the level of VCAM-1 expression (figure 1E). Indeed, a graded tracer uptakeof 
1.4 ± 0.2, 2.5 ± 0.2 and 3. 2 ± 0.3 %ID/g was observed in low, moderate and strong VCAM-1 
expressing lesions, respectively (P<0.001 between low and moderate or strong, and P = 
0.029 between moderate and high). 
 
Non invasive evaluation of a reference therapy 
 
Lesion extension. 
The results are presented in Table 1 and Figure 1. Similar cholesterol levels were observed 
between treated and control animals prior to switching from chow to western dietcontaining 
(treated) or not (control) atorvastatin (20.3±2.2 vs 18.8±2.2 mmol/L, P = NS). Average 
atorvastatin intake was 12.9±0.2 mg/kg/day/animal and resulted in a significant 29.1% 
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decrease in total cholesterol level in the atorvastatin-treated group in comparison with the 
control group (60.7±6.6 vs 85.5±8.1 mmol/L; P = 0.034). Lesion extension in the aortic sinus 
was significantly reduced by 39.9% in the treated group in comparison to that of the control 
group (0.70 ± 0.07 vs 1.07 ± 0.11 mm2, P = 0.011) (Table 1 and suppl. fig. 1). Finally, modest 
variations in VCAM-1 expression in the aortic sinus were observed between control and 
treated animals following immunohistochemistry(suppl. fig. 1). 
 
In vivo SPECT/CT imaging. 
99mTc-cAbVCAM1-5 allowed the non-invasive monitoring of atorvastatin effect on 
atherosclerosis. Indeed, 99mTc-cAbVCAM1-5 uptake in aortic lesions was readily visible on 
SPECT images (figure 2) and the trend towards a reduction of 99mTc-cAbVCAM1-5 uptake 
that was observed in 25 weeks-old atorvastatin-treated mice (0.83 ± 0.09 %ID/cm3vs 0.97 ± 
0.06 %ID/cm3 in control group, P=NS) reached statistical significance at 35 weeks (0.87 ± 
0.06 %ID/cm3vs 1.11 ± 0.09 %ID/cm3 in control group, P = 0.035). Contrast-CT acquisitions 
allowed the accurate delineation of the ascending aorta in all animals, and contrast-CT 
based SPECT quantification was reproducible, with inter- and intra- experimenter ICC of 0.97 
and 0.90, respectively (Figure 3).  
 
Ex vivo gamma-well counting. 
99mTc-cAbVCAM1-5 biodistribution is presented in Table 2. 99mTc-cAbVCAM1-5 uptake in 
atorvastatin-treated animals was significantly decreased by 24.1 % in the ascending aorta of 
atorvastatin-treated animals (0.9 ± 0.1 vs 1.2 ± 0.1 %ID/g, P = 0.015). The tracer was mainly 
eliminated through the kidneys (138.7 ± 8.6 %ID/g) with minimal uptake in all other 
investigated tissues (< 2 %ID/g) with the exception of lymphoid organs. Indeed, tracer uptake 
in the spleen, thymus, bone marrow and lymph node was of 8.8 ± 0.7; 2.1 ± 0.2; 4.0 ± 0.4 
and 2.8 ± 0.3 %ID/g, respectively.  
 
Exvivo autoradiography. 
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In both groups, robust 99mTc-cAbVCAM1-5 uptake in atherosclerotic lesions was readily 
observable at the level of the aortic sinus (suppl. fig. 1 A-D). A strong and statistically 
significant 41.5% decrease in 99mTc-cAbVCAM1 total uptake was observed in the 
atorvastatin-treated group in comparison to that of the control group (table 3). Indeed 99mTc-
cAbVCAM1 uptake represented 8.9x10-5 ± 1.1x10-5%ID/slice in the control group and 5.2 10-5 
± 0.9 10-5 %ID/slice in the treated group. Interestingly,autoradiography quantification 
indicated a trend toward a 15.2% decrease of 99mTc-cAbVCAM1-5 concentration in 
atherosclerotic lesions from atorvastatin-treated animalswhen tracer uptake was corrected 
for plaque area (1.8 ± 0.2 %ID/g vs 2.1 ± 0.2 %ID/g in control group, P=NS),  
 
Comparison between SPECT/CT, autoradiography, and gamma-well counting data 
Further data analysis indicated that SPECT/CT quantification was strongly correlated to ex 
vivo gamma-well counting biodistribution (r = 0.83; P<0.0001) (figure 4A). Moreover, the 
results from SPECT/CT image quantification were significantly correlated to 99mTc-
cAbVCAM1 total uptake in aortic sinus lesions as determined by autoradiography (r = 0.51; P 
= 0.04), rather than to 99mTc-cAbVCAM1 concentration or to lesion area (P=NS for both) 
(figure 4 B-D). 
 
Discussion 
 
Atorvastatin significantly reduced lesion extension in the aortic sinus of ApoE-deficient mice, 
and this effect was successfully monitored non-invasively using 99mTc-cAbVCAM1-5 
molecular imaging with high reproducibility. 99mTc-cAbVCAM1-5 is therefore a specific, 
sensitive and reproducible tool for the imaging of VCAM-1 expression in murine 
atherosclerotic lesions.  
 
Effect of statin therapy.The anti-atherosclerotic effects of statins are mainly mediated by 
their cholesterol-lowering properties leading to reduced plaque volume(18). In addition, 
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statins also exert pleiotropic effects which go beyond the drop in plasma cholesterol and 
which mainly result in an inhibition of inflammatory processes responsible for vulnerable 
plaque development(19,20). However, depending on the dose &duration of the treatment and 
on study design, the reduction in plasma cholesterol, plaque volume and inflammatory 
markers are not always consistently or concomitantly observed in experimental studies. 
Indeed, in an ApoE-deficient mouse model of carotid artery lesions induced by perivascular 
collar placement, Bot and coll. observed that a low dose of atorvastatin (0.003%w/w) 
significantly reduced lesion size by 40% despite no reduction in total plasma cholesterol or 
macrophage positive areas(15). Conversely, a twelve week atorvastatin treatment (1 
mg/kg/day) resulted in a significant reduction in the circulating inflammatory markers 
Interleukin-6 and Monocyte Chemoattractant Protein-1 as well as macrophage infiltration in 
aortic lesions of apoE-deficientmice  despite no significant change in plasma cholesterol and 
plaque area(21).  
 
The western-type diet-fed apoE-deficient mice that were used in the present study had a 
mean total blood cholesterol level of 85.5±8.1 mmol/L, in good accordance with the 28-114 
mmol/L range reported on a similar model by Nakashima and coll(22). Supplementation of 
the western-type diet with 0.01% w/w atorvastatin resulted in an expected administered dose 
of 10mg/kg/day(16). Atorvastatin significantly decreased total cholesterol by 29% and lesion 
size by 40%. These results are in accordance with the range of atorvastatin-induced 
modifications reported by other groups(16,17). Modest changes in the lesional expression of 
VCAM-1 were observed in atorvastatin-treated animals, in contrast with other studies 
showing a significant 30-80% reduction in VCAM-1 expression(16,17,23). However, 
Nachtigal and coll found no significant change in VCAM-1 lesion expression in double knock-
out, LDLR-/-ApoE-/- mice in the presence of atorvastatin at a similar dose to that used in the 
present study(24). 
13 
 
Overall, atorvastatin administered at a dose of 0.01% w/w for 20 weeks to ApoE-deficient 
mice fed a western-type diet therefore had significant anti-atherogenic effects that allowed 
the evaluation of the potential of 99mTc-cAbVCAM1-5 for treatment effect monitoring.  
 
Sensitivity of 99mTc-cAbVCAM1-5 imaging. 
99mTc-cAbVCAM1-5 uptake occurred in atherosclerotic lesions as well as in lymphoid organs 
constitutively expressing VCAM-1 following tracer injection to ApoE-deficient mice fed a 
western type diet, in accordance with previously published results(10). Autoradiography and 
immunohistochemistryindicatedthat99mTc-cAbVCAM1-5 uptake in atherosclerotic lesion 
significantly increased together with the level of VCAM-1 expression.  Importantly, 99mTc-
cAbVCAM1-5lesion uptake was significantly reduced in 35 weeks-old atorvastatin-treated 
mice as indicated by ex vivo GWC and autoradiography as well as in vivonon 
invasiveSPECT/CT molecular imaging. In vivo image quantification was reproducible and 
yielded results that were highly correlated withtracer biodistributionas determined ex vivo. 
 
More precisely, VOIsfrom in vivo images were reproducibly drawn at the level of the aortic 
sinus based on contrast-CT images. In the hypothesis that the VOI exclusively contained 
atherosclerotic lesional tissues and according to the fact that 99mTc-cAbVCAM1-5 uptake in 
murine atherosclerotic lesion significantly increased together with the level of VCAM-1 
expression, SPECT quantification would then have directly reflected the levelof VCAM-1 
expression in atherosclerotic lesions. However, due to the relatively small size of 
atherosclerotic lesions, and despite the use of a state-of-the-art, sub-millimetric resolution 
system, partial volume effect necessarily occurred while performing SPECT imaging of 
murine aortic plaques. Therefore, the VOI used for the assessment of tracer uptake in 
atherosclerotic lesions contained a mixture of the various tissues composing the aortic sinus 
– i.e. atherosclerotic lesions, normal vessel wall and blood – rather than the atherosclerotic 
lesion only. Consequently, the total activity in a VOI, and therefore the result of in vivo 
quantification, depended not only upon the level of VCAM-1expression in the lesions but also 
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upon the amount of lesions included in the VOI, and therefore lesion extension. This was 
demonstrated in the present study by the fact that the results from SPECT/CT image 
quantification were significantly correlated to 99mTc-cAbVCAM1 total uptake in aortic sinus 
lesions as defined by the product of 99mTc-cAbVCAM1 concentration in lesion by lesion 
volume – rather than with any one of these two parameters considered separately.In 
conclusion, 99mTc-cAbVCAM1-5 SPECT/CT imaging allowed the sensitive and reproducible 
non-invasive quantification of the net effect of a reference statin therapy on lesion size and 
inflammation in the apoE-deficient mouse model of atherosclerosis. 
 
Comparison with other radiotracers and molecular targets. 
The sensitivity of 99mTc-cAbVCAM1-5 imaging favorably compared with previously evaluated 
radiotracers. In a rabbit model of atherosclerosis,Haider and coll. observed a decrease in the 
uptake of two SPECT agents directed against matrix metalloproteinases(MPI) and apoptosis 
(AA5)followingtreatment with fluvastatin(25).Although SPECT image quantification was not 
performed,thesequalitative visual observations were further confirmed by quantitative ex vivo 
analysis. Similarly, a significant 30% reduction in18F-4V was found by in vivo positron 
emission tomography(PET)image quantification in a similar model to that employed in the 
present study(23). A number of studies have investigated the potential of 18F-FDG for the 
non-invasive assessment of treatment efficacy. Such potentialhas been validated in rabbits 
using the anti-oxydantprobucol(26), thereby allowing the use of 18F-FDGfor the evaluation of 
novel therapeutics in preclinical(27,28) and clinical studies(12,29). However, high myocardial 
uptake remains a potential limitation for the imaging of coronary lesions with 18F-FDGdespite 
the use of imaging protocols aimed at reducing myocardial tracer uptake(30). 
VCAM-1 protein is strongly and specifically expressed during the inflammatory process, and 
therefore constitutes a highly relevant target for VP imaging, similarly to other inflammatory 
markers such as macrophages. Other biological processes related to plaque rupture such as 
apoptosis, matrix degradation or neoangiogenesis(31) have been proposed as potential 
targets. These processes occur at different times and intraplaque locations over the course 
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of plaque development. Ultimately, prospective clinical trials will be needed in order to select 
the most appropriate target and corresponding imaging agent. 
 
Conclusions 
SdAbsderived radiotracers have been  initially developed in the field of oncology, and a first 
phase I clinical trial is currently been performed with an anti-human epidermal growth factor 
receptor 2radiotacer for PET imaging of breast cancer patients. Thereafter, anti-VCAM-1 
sdAb extended the field of sdAb imaging to cardiovascular applications. As demonstrated in 
the present study, 99mTc-cAbVCAM1-5 is a sensitive tool for the non-invasive imaging of 
atherosclerosis. Indeed, 99mTc-cAbVCAM1-5 uptake in mouse atherosclerotic lesions was 
correlated to the level of VCAM-1 expression, and the effect of a reference therapy was 
successfully and reproducibly monitored non-invasively by SPECT/CT imaging quantification. 
99mTc-cAbVCAM1-5 therefore exhibits suitable characteristics for evaluation of novel anti-
atherogenic agents. 
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Figure Legends 
 
FIGURE 1.99mTc-cAbVCAM1-5 uptake and VCAM-1 expression. A and C: Representative 
VCAM-1 immunostainings performed on aortic arch lesions of ApoE-deficient mice. B and D: 
99mTc-cAbVCAM1-5 ARG imaging performed on adjacent slices. Strong 99mTc-cAbVCAM1-5 
uptake was observed on atherosclerotic lesions expressing high level of VCAM-1 (blue 
asterisks), in comparison to atherosclerotic lesions expressing low levels of VCAM-1 (black 
asterisks). This result was further confirmed by autoradiography quantification (E). Scale bar: 
500µm; Autoradiography calibration bar is expressed in %ID/g.
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FIGURE2.In-vivo SPECT/CT imaging.Representative example of sagittal (1st column), 
coronal (2nd column) and transaxial (3rd column) views centered on the ascending aorta of 
control group mouse are presented here. Myocardial cavities and major vessels including the 
aorta were easily identifiable on contrast-CT images (1st row), allowing to precisely defining 
four VOIs along the aortic sinus and ascending aorta (2nd row).99mTc-cAbVCAM1-5 uptake 
was readily visible by SPECT within the aorta (red arrow), as well as in tissues constitutively 
expressing VCAM-1 such as the lymph nodes (asterisks) and thymus (t). SPECT scale was 
normalized from 0.3 to 3%ID/cm3.  
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FIGURE3.SPECT/CT quantification.  The reduction of 99mTc-cAbVCAM1-5 uptake in treated 
mice aorta was successfully monitored in vivo by SPECT/CT imaging (A). Furthermore, 
contrast-CT based SPECT analysis provided robust quantifications, as determined by intra-
experimenter correlation (B) and inter/intra experimenter ICCs (C). 
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FIGURE4.Comparison between in vivo and ex vivo quantifications of 99mTc-
cAbVCAM1-5 uptake in atherosclerotic lesions.SPECT/CT quantification was compared 
to ex vivo biodistribution in samples constituted of the aortic sinus and ascending aorta (A), 
as well as to the autoradiography quantification results either expressed as a total uptake in 
lesions per slice (B) or as a concentration (C), and to plaque area (D).White markers: Control 
group. Black markers: Treated group. 
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Tables 
 
Parameter Unit control treated % change 
Tot. Cho. 
Chow diet mmol/L 20.3±2.2 18.8±2.2 NS 
Western diet mmol/L 85.5±8.1 60.7±6.6 - 29.1 (P = 0.034) 
Lesion area mm
2
 1.07±0.11 0.70±0.07 - 33.9 (P = 0.011) 
 
TABLE 1.Effect of treatment on lesions extension.Atorvastatin 0.01% significantly 
decreased total plasma cholesterol as well as lesion extension at the level of the aortic sinus.  
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  Control  Treated 
As. Aorta 1.2±0.1 0.9±0.1* 
Blood 0.6±0.1 0.5±0.0 
Heart 0.3±0.0 0.3±0.0 
Lung 1.7±0.1 1.8±0.1 
Liver 1.5±0.1 1.4±0.1 
SM 0.1±0.0 0.3±0.1 
SG 0.7±0.2 0.7±0.1 
Thyroid 1.2±0.2 0.9±0.2 
Stomach 0.7±0.1 0.7±0.1 
Bile 0.4±0.0 0.5±0.1 
Kidney 138.7±8.6 165.0±6.8 
Spleen 8.8±0.7 7.9±0.5 
Thymus 2.1±0.2 1.8±0.2 
BM 4.0±0.4 4.1±0.7 
LN 2.8±0.3 2.7±0.2 
 
TABLE 2.Ex vivo biodistribution of 99mTc- cAbVCAM1-5 3h post-injection in ApoE-
deficient mice. Results are expressed as %ID/g (mean ± s.e.m.). * P =0.015 vs control 
group. SM, skeletal muscle; SG, salivary glands; BM, bone marrow; LN, lymph node.
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Parameter Unit Control Treated % change 
Total uptake %ID/slice (.10-6) 8.9 ± 1.2 5.2 ± 0.9 - 41.5 (P=0.024) 
Concentration %ID/g 2.1 ± 0.2 1.8 ± 0.2 NS 
 
TABLE 3.Ex vivo autoradiography quantification on the aortic sinus 
lesions.Atorvastatin therapy resulted in a statistically significant decrease in 99mTc-
cAbVCAM1 total uptake in atherosclerotic lesions. Furthermore, there was also a trend 
toward a 15.2% decrease of 99mTc-cAbVCAM1-5 concentration in atorvastatin-treated group 
when tracer uptake was corrected for plaque area (P = NS) 
